DOCSLIB.ORG

Table S1. Full Ksrepo Results for GSE58477 and GSE63409

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table S1. Full Ksrepo Results for GSE58477 and GSE63409 Table S1. Full ksRepo results for GSE58477 and GSE63409. Compound Name FDR FDR GSE58477 GSE63409 ABACAVIR 0.4169357639 0.6971455224 ABIRATERONE 1 1 ACAMPROSATE 0.1591 0.5654086538 ACARBOSE 0.7406241033 0.8583732661 ACEBUTOLOL 0.8232993631 0.9806125131 ACENOCOUMAROL 0.971244382 0.9906314969 ACETAMINOPHEN 1 1 ACETAZOLAMIDE 0.4080291971 0.5654086538 ACETIC ACID 0.2442463235 0.3610897436 ACETOHYDROXAMIC ACID 0.7857113821 0.8583732661 ACETOPHENAZINE 0.971244382 1 ACETYLCARNITINE 0.5007687927 0.6107492114 ACETYLCHOLINE 0.4484130982 0.6223020528 ACETYLCYSTEINE 0.9886436464 0.905734104 ACITRETIN 0.7917460317 0.8976439483 ACRIVASTINE 1 0.8601348808 ADAPALENE 0.1723412698 0.6085267857 ADEFOVIR DIPIVOXIL 1 0.9517829241 ADENINE 1 1 ADENOSINE 0.839575 0.8794634293 ADENOSINE MONOPHOSPHATE 0.3943003731 0.7940931721 ADENOSINE TRIPHOSPHATE 0.45875625 0.6107492114 ADINAZOLAM 0.5889218456 0.9583838106 ADO-TRASTUZUMAB EMTANSINE 0.7514295875 0.9929090909 AJMALINE 0.4484130982 0.6971455224 ALBENDAZOLE 0.359606599 0.8794634293 ALENDRONATE 0.9508660508 0.8083940853 ALFACALCIDOL 0.4558646617 0.5654086538 ALFENTANIL 0.7097967791 0.6389606742 ALFUZOSIN 0.6311230637 0.5654086538 ALISKIREN 0.5421933472 0.7166666667 0.0358333333 ALITRETINOIN 0.026875 3 ALLOPURINOL 0.7559922316 0.6971455224 ALLYLESTRENOL 0.971244382 1 ALMOTRIPTAN 0.4484130982 0.6085267857 ALPHA-LINOLENIC ACID 0.446463964 0.6971455224 ALPRAZOLAM 0.790246996 0.9929090909 ALPRENOLOL 0.3661872146 0.6971455224 ALPROSTADIL 0.4248458904 0.7612788906 ALUMINUM HYDROXIDE 0.1738970588 0.5654086538 ALVIMOPAN 0.498966895 0.5866049383 AMANTADINE 0.653177496 0.8174084125 AMBRISENTAN 0.3107012195 0.6085267857 AMIFOSTINE 1 0.7230427046 AMIKACIN 0.3726982379 0.5654086538 AMILORIDE 0.8483209877 0.9906314969 AMINOCAPROIC ACID 1 0.8583732661 AMINOGLUTETHIMIDE 0.5421933472 1 AMINOLEVULINIC ACID 0.9356154748 0.9806125131 AMINOPHYLLINE 0.1491836735 0.369695122 AMINOSALICYLIC ACID 0.968594457 0.5971493902 AMIODARONE 0.5548802395 0.9929090909 AMITRIPTYLINE 0.1663207547 0.5866049383 AMLEXANOX 0.493534279 0.6971455224 AMLODIPINE 0.4296587302 0.5752192982 AMMONIUM CHLORIDE 0.8483209877 0.7611801242 AMOBARBITAL 0.4484130982 0.7356261023 AMODIAQUINE 0.8463957816 0.6085267857 AMOXAPINE 0.4484130982 0.7499748322 AMOXICILLIN 0.7105206738 0.8583732661 AMPHETAMINE 0.4484130982 0.7651567278 AMPHOTERICIN B 1 1 AMPICILLIN 0.7182293233 0.6085267857 AMPRENAVIR 0.7105408472 0.6693702771 AMRINONE 0.621131993 0.6072807018 AMSACRINE 1 0.7611801242 ANAGRELIDE 0.5059829545 0.6085267857 ANASTROZOLE 0.4169357639 0.6223020528 ANTAZOLINE 0.4484130982 0.6971455224 ANTIPYRINE 0.3107012195 0.5654086538 APOMORPHINE 0.3726982379 0.6107492114 APREPITANT 0.7087037037 0.7373036649 APRINDINE 0.3661872146 0.7669742814 ARANIDIPINE 0.761520979 0.7612788906 ARGATROBAN 0.7520438472 0.902125 0.0716666666 ARIPIPRAZOLE 7 0.3610897436 ARSENIC TRIOXIDE 1 0.9663302503 ARTEMETHER 0.4708656174 0.7450548986 ARTESUNATE 1 0.9683161605 ASPARTAME 0.653177496 0.9806125131 ASTEMIZOLE 0.0846969697 0.5635606061 ATENOLOL 0.6048851103 0.7611801242 ATOVAQUONE 0.3931552419 0.5866049383 ATROPINE 0.653177496 0.6126164596 AURANOFIN 0.8151619171 0.8467562254 AVOBENZONE 0.5722370937 0.7693882175 AZACITIDINE 0.4484130982 0.5752192982 AZATADINE 0.2442463235 0.5866049383 AZATHIOPRINE 0.9027194543 0.7669742814 AZELAIC ACID 0.2972058824 0.6085267857 AZELASTINE 0.3917975207 0.6166411043 AZELNIDIPINE 0.971244382 1 AZITHROMYCIN 0.7097967791 0.6971455224 AZTREONAM 0.4296587302 0.6971455224 BACLOFEN 0.5421933472 0.5654086538 BAMBUTEROL 0.8879706235 0.9088523645 BAZEDOXIFENE 0.8626219512 0.8910414201 0.0958783783 BECLOMETHASONE 8 0.4985775862 0.0761458333 0.0358333333 BELINOSTAT 3 3 BENAZEPRIL 0.7105408472 0.8954117647 BENDROFLUMETHIAZIDE 0.9508660508 0.9734142395 BENIDIPINE 0.7337030347 0.9946190716 BENZOCAINE 0.6350428816 0.7722774481 BENZOIC ACID 0.6007235622 0.5654086538 BENZOPHENONE 1 0.7612788906 BENZOYL PEROXIDE 0.7705409154 0.9138115693 BENZPHETAMINE 0.4296587302 0.9806125131 BENZYDAMINE 0.7337030347 0.6085267857 BENZYL ALCOHOL 1 0.8045353675 BENZYL BENZOATE 0.6007235622 0.858919598 BEPRIDIL 0.653177496 0.9186028571 BETAMETHASONE 1 0.8583732661 BETAXOLOL 0.5722370937 0.9806125131 BETHANECHOL 0.4955549065 0.6971455224 BEXAROTENE 0.8166131105 0.9516275168 BEZAFIBRATE 0.7874120433 0.6971455224 BICALUTAMIDE 1 1 BIFONAZOLE 0.7097967791 0.9630452563 BIOTIN 0.8570981595 0.6332276657 BISOPROLOL 0.359606599 0.6971455224 BIVALIRUDIN 0.6525 0.9185469108 BLEOMYCIN 1 0.8604036295 BOPINDOLOL 0.4484130982 0.6971455224 BORTEZOMIB 1 1 BOSENTAN 0.7891510067 0.7423758562 BOSUTINIB 0.7891510067 0.6971455224 BRINZOLAMIDE 0.5138789238 0.6085267857 BROMAZEPAM 0.9759899889 0.6971455224 BROMFENAC 0.4313479624 0.6830783133 BROMHEXINE 0.4484130982 0.6971455224 0.0815517241 BROMOCRIPTINE 4 0.6210756677 BROMPHENIRAMINE 0.3604726368 0.6425977654 BROTIZOLAM 0.6375042517 0.8583732661 BUDESONIDE 0.1212234043 0.5654086538 BUMETANIDE 0.1075 0.6971455224 BUPIVACAINE 0.433993808 0.8858820024 BUPRANOLOL 0.7628596369 0.890513658 BUPRENORPHINE 0.6094230769 0.6085267857 BUPROPION 1 0.9929090909 BUSERELIN 0.7337030347 0.954796544 0.0996341463 BUSPIRONE 4 0.6085267857 BUSULFAN 1 1 BUTENAFINE 0.4381935976 0.6085267857 BUTOCONAZOLE 0.3943003731 0.7611801242 BUTORPHANOL 0.498966895 0.5866049383 CABERGOLINE 0.653177496 0.6085267857 CAFFEINE 0.9046010638 0.9806125131 CALCITRIOL 0.2442463235 0.2597916667 CALCIUM CARBONATE 0.9503099652 0.7611801242 CALCIUM CHLORIDE 0.1670089286 0.6971455224 CALFACTANT 0.9380908033 0.8794634293 CAMPHOR 0.3651913876 0.5866049383 CANAGLIFLOZIN 0.2442463235 0.3610897436 CANDESARTAN 0.3107012195 0.6106292517 CANGRELOR 0.6525 0.5654086538 CAPECITABINE 1 0.8794634293 CAPSAICIN 1 1 CARBACHOL 0.4369248466 0.7992587413 CARBAMAZEPINE 1 0.9831959034 CARBIDOPA 0.5191055556 0.6085267857 CARBIMAZOLE 0.6129991087 0.6106292517 CARBINOXAMINE 0.4484130982 0.6971455224 CARBON DIOXIDE 0.839575 0.9583838106 CARBOPLATIN 0.973519037 0.9929090909 CARFILZOMIB 1 0.9201022727 CARISOPRODOL 0.4296587302 0.6085267857 CARMUSTINE 0 0.43215 CARTEOLOL 0.5722370937 0.9806125131 CARVEDILOL 0.05375 0.6177140673 CASPOFUNGIN 0.5421933472 0.6971455224 CEFACLOR 0.2238761468 0.6971455224 CEFADROXIL 0.4484130982 0.6971455224 CEFAZOLIN 0.5421933472 0.9512486002 CEFDINIR 0.4400679758 0.6971455224 CEFEPIME 1 0.9929090909 CEFMETAZOLE 1 0.791942446 CEFOTAXIME 0.4484130982 0.3610897436 CEFOTIAM 0.4400679758 0.6971455224 CEFOXITIN 0.6251826087 0.6107492114 CEFPODOXIME 0.653177496 0.6085267857 CEFTAZIDIME 0.7042757009 0.7230427046 CEFTIBUTEN 0.3479768786 0.750882107 CEFTIZOXIME 0.6211111111 0.8464388962 CEFTRIAXONE 0.8317676768 0.8654480841 CEFUROXIME 0.5722370937 0.6085267857 CELECOXIB 1 0.9806125131 CELIPROLOL 0.8278594148 0.9737419355 CEPHALEXIN 0.4296587302 0.6971455224 CEPHALORIDINE 0.4400679758 0.6971455224 CERULENIN 1 1 CERULETIDE 0.413046595 0.6389606742 CETIRIZINE 0.839575 0.7450548986 CETRORELIX 0.5191055556 0.6971455224 CHENODEOXYCHOLIC ACID 0.4484130982 0.6085267857 CHLORAL HYDRATE 0.2487857143 0.6458811475 CHLORAMBUCIL 1 0.7611801242 CHLORAMPHENICOL 0.5548737374 0.9241827469 0.0955555555 CHLORCYCLIZINE 6 0.6126164596 CHLORDIAZEPOXIDE 0.6094230769 0.6107492114 CHLORHEXIDINE 0.4484130982 0.6971455224 CHLOROQUINE 0.985 0.8583732661 CHLORPROMAZINE 0.7145588235 0.8794634293 CHLORPROPAMIDE 0.2716554054 0.7611801242 CHLORPROTHIXENE 0.4484130982 0.3610897436 CHLORTETRACYCLINE 0.2017134831 0.6106292517 CHLORTHALIDONE 0.5421933472 0.7166666667 CHLORZOXAZONE 0.4484130982 0.6085267857 CHOLECALCIFEROL 0.9652885714 0.8583732661 CHOLIC ACID 0.1926041667 0.5654086538 CHOLINE 0.2963322368 0.6425977654 CHORIONIC GONADOTROPIN 0.8492632552 0.7055550459 CHROMIC CHLORIDE 0.2734395973 0.5866049383 CICLESONIDE 0.8317676768 0.7992587413 CICLOPIROX 0.8537853629 0.7562687813 CIDOFOVIR 1 1 CILAZAPRIL 0.3065483871 0.5654086538 CILNIDIPINE 0.3767173913 0.6971455224 CILOSTAZOL 0.4708656174 0.6971455224 0.0716666666 CIMETIDINE 7 0.6303125 CINITAPRIDE 0.7857113821 0.7611801242 CINNARIZINE 0.6094230769 0.6107492114 CINOXACIN 0.4296587302 0.6971455224 CIPROFLOXACIN 0.5548737374 0.8464388962 CISAPRIDE 0.359606599 0.7651567278 CISPLATIN 1 1 CITALOPRAM 0.2017134831 0.7071023766 CLADRIBINE 1 0.9791247323 CLARITHROMYCIN 0.3661872146 0.6389606742 CLEMASTINE 0.2442463235 0.5866049383 CLENBUTEROL 0.2099292453 0.2597916667 CLIDINIUM 0.4484130982 0.6971455224 CLINDAMYCIN 0.5330501089 0.6971455224 CLINOFIBRATE 0.729624256 0.6971455224 CLOBAZAM 0.9652885714 0.8944811321 CLOFARABINE 1 1 CLOFAZIMINE 0.4080291971 0.5458984375 CLOFIBRATE 1 0.9806125131 CLOMIPRAMINE 0.2393043478 0.5866049383 CLONAZEPAM 0.3943003731 0.7611801242 CLONIDINE 0.2493085106 0.5866049383 CLOPIDOGREL 0.4708656174 0.6830783133 CLOTRIMAZOLE 1 0.8583732661 CLOXACILLIN 0.6094230769 0.6107492114 CLOXAZOLAM 0.6211111111 0.3610897436 CLOZAPINE 0.026875 0.4139893617 COCAINE 0.359606599 0.5752192982 CODEINE 0.6211111111 0.7036003683 COLCHICINE 1 0.9906314969 COPPER 1 1 COSYNTROPIN 0.7891510067 0.8078832873 CREATINE 0.643739531 0.902125 CRIZOTINIB 0.985 0.6322615607 CUPRIC CHLORIDE 1 1 CYAMEMAZINE 0.653177496 0.7992587413 CYCLOBENZAPRINE 0.4484130982 0.6971455224 CYCLOPHOSPHAMIDE 0.4296587302 0.6085267857 CYCLOSERINE 0.7973854712 0.9690140845 CYCLOSPORINE 1 1 CYCLOTHIAZIDE 0.4484130982 0.939229684 CYPROHEPTADINE 0.205127551 0.4139893617 CYPROTERONE ACETATE 0.359606599 0.8794634293 CYSTEAMINE 0.5356344902 0.9929090909 CYTARABINE 0 0 CYTISINE 0.4296587302 0.9929090909 DABRAFENIB 0.839575 0.791942446 DACARBAZINE 1 0.791942446 DACTINOMYCIN 0.2087980769 0.8858820024 DALTEPARIN 0.9380908033 0.8583732661 DANAZOL 0.7412732475
Load more

Recommended publications
  • Wo 2009/081169 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
    [Show full text]
  • Restoration of Temozolomide Sensitivity by PARP Inhibitors In
    Published OnlineFirst January 3, 2020; DOI: 10.1158/1078-0432.CCR-19-2000 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair Fumi Higuchi1,2, Hiroaki Nagashima1, Jianfang Ning1,3, Mara V.A. Koerner1, Hiroaki Wakimoto1, and Daniel P. Cahill1 ABSTRACT ◥ Purpose: Emergence of mismatch repair (MMR) deficiency is a Results: While having no detectable effect in MSH6 wild-type frequent mechanism of acquired resistance to the alkylating che- GBMs, PARPi selectively restored TMZ sensitivity in MSH6- motherapeutic temozolomide (TMZ) in gliomas. Poly(ADP-ribose) deficient GBM cells. This genotype-specific restoration of activity polymerase inhibitors (PARPi) have been shown to potentiate TMZ translated in vivo, where combination treatment of veliparib cytotoxicity in several cancer types, including gliomas. We tested and TMZ showed potent suppression of tumor growth of whether PARP inhibition could re-sensitize MSH6-null MMR- MSH6-inactivated orthotopic xenografts, compared with TMZ deficient gliomas to TMZ, and assessed the role of the base excision monotherapy. Unlike PARPi, genetic and pharmacological block- repair (BER) DNA damage repair pathway in PARPi-mediated age of BER pathway did not re-sensitize MSH6-inactivated GBM effects. cells to TMZ. Similarly, CRISPR PARP1 knockout did not re- Methods: Isogenic pairs of MSH6 wild-type and MSH6-inacti- sensitize MSH6-inactivated GBM cells to TMZ. vated human glioblastoma (GBM) cells (including both IDH1/2 Conclusions: PARPi restoration of TMZ chemosensitivity in wild-type and IDH1 mutant), as well as MSH6-null cells derived MSH6-inactivated glioma represents a promising strategy to from a patient with recurrent GBM were treated with TMZ, the overcome acquired chemoresistance caused by MMR deficiency.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • Identification of Compounds That Rescue Otic and Myelination
    RESEARCH ARTICLE Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant Elvira Diamantopoulou1†, Sarah Baxendale1†, Antonio de la Vega de Leo´ n2, Anzar Asad1, Celia J Holdsworth1, Leila Abbas1, Valerie J Gillet2, Giselle R Wiggin3, Tanya T Whitfield1* 1Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; 2Information School, University of Sheffield, Sheffield, United Kingdom; 3Sosei Heptares, Cambridge, United Kingdom Abstract Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also results in defects in the inner ear: otic tissue fails to down-regulate versican gene expression and morphogenesis is disrupted. We have designed a whole-animal screen that tests for rescue of both up- and down-regulated gene expression in mutant embryos, together with analysis of weak and strong alleles. From a screen of 3120 structurally diverse compounds, we have identified 68 that reduce versican b expression in the adgrg6 mutant ear, 41 of which also restore myelin basic protein gene expression in Schwann cells of mutant embryos. Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates for molecules that may interact directly with the Adgrg6 receptor. Our pipeline provides a powerful approach for identifying compounds that modulate GPCR activity, with potential impact for future drug design. DOI: https://doi.org/10.7554/eLife.44889.001 *For correspondence: [email protected] †These authors contributed Introduction equally to this work Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in Langenhan et al., Competing interest: See 2016; Patra et al., 2014).
    [Show full text]
  • Calcium Channel Blocker As a Drug Candidate for the Treatment of Generalised Epilepsies
    UNIVERSITAT DE BARCELONA Faculty of Pharmacy and Food Sciences Calcium channel blocker as a drug candidate for the treatment of generalised epilepsies Final degree project Author: Janire Sanz Sevilla Bachelor's degree in Pharmacy Primary field: Organic Chemistry, Pharmacology and Therapeutics Secondary field: Physiology, Pathophysiology and Molecular Biology March 2019 This work is licensed under a Creative Commons license ABBREVIATIONS AED antiepileptic drug AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ANNA-1 antineuronal nuclear antibody 1 BBB blood-brain barrier Bn benzyl BnBr benzyl bromide BnNCO benzyl isocyanate Boc tert-butoxycarbonyl Bu4NBr tetrabutylammonium bromide Ca+2 calcium ion CACNA1 calcium channel voltage-dependent gene cAMP cyclic adenosine monophosphate CCB calcium channel blocker cGMP cyclic guanosine monophosphate CH3CN acetonitrile Cl- chlorine ion Cmax maximum concentration CMV cytomegalovirus CTScan computed axial tomography DCM dichloromethane DIPEA N,N-diisopropylethylamine DMF dimethylformamide DMPK drug metabolism and pharmacokinetics DNET dysembryoplastic neuroepithelial tumours EEG electroencephalogram EPSP excitatory post-synaptic potential FDA food and drug administration Fe iron FLIPR fluorescence imaging plate reader fMRI functional magnetic resonance imaging GABA γ-amino-α-hydroxybutyric acid GAD65 glutamic acid decarboxylase 65 GAERS generalised absence epilepsy rat of Strasbourg GluR5 kainate receptor GTC generalised tonic-clonic H+ hydrogen ion H2 hydrogen H2O dihydrogen dioxide (water)
    [Show full text]
  • Endocrine Disrupting Compounds and Prostate Cell Proliferation
    Review Article Clinics in Oncology Published: 18 Oct, 2016 Endocrine Disrupting Compounds and Prostate Cell Proliferation Joubert Banjop Kharlyngdoh and Per-Erik Olsson* Department of Biology, Örebro University, Sweden Abstract Epidemiological, in vitro and animal studies have indicated that Endocrine Disrupting Compounds (EDCs) influence the normal growth and development of the prostate as well as development and progression of prostate cancer. This has been linked to an increased presence of environmental chemicals that interfere with hormonal signaling. Many of these effects appear to be associated with interferences with steroid hormone receptor signaling or by affecting steroidogenesis. Currently, there is abundant evidence from epidemiological studies linking pesticides and EDCs with elevated prostate cancer risk. Bisphenol-A, a known EDC, has been shown to promote induction of Prostate Specific Antigen (PSA), which is a biomarker for prostate cancer, in the LNCaP human prostate carcinoma cells, and to increase prostate carcinogenesis in animal models. Our research has focused on AR signaling and identification of novel androgenic and anti-androgenic EDCs. Using prostate cancer cell lines we have shown that the AR agonist, TBECH, and antagonist ATE, which is also a partial ART877A agonist, induce PSA expression. With the increasing presence of these EDCs in indoor and outdoor air, follows an increased risk of disturbed prostate development, regulation and function. Hence, identification of the contribution of EDCs to prostate cancer
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Table of Contents
    NTICANCER ESEARCH InternationalA Journal of Cancer ResearchR and Treatment ISSN: 0250-7005 Volume 24, Number 4, July-August 2004 Contents Experimental Studies Inhibition of the Human Apurinic/Apyrimidinic Endonuclease (Ape1) Repair Activity and Sensitization of Breast Cancer Cells to DNA Alkylating Agents with Lucanthone. M. LUO, M.R. KELLEY (Indianapolis, Indiana, USA)........................................................................................................................................................... 2127 Androgen Withdrawal Inhibits Tumor Growth and is Associated with Decrease in Angiogenesis and VEGF Expression in Androgen-Independent CWR22Rv1 Human Prostate Cancer Model. L. CHENG, S. ZHANG, C.J. SWEENEY, C. KAO, T.A GARDNER, J.N. EBLE (Indianapolis, Indiana, USA) .................................. 2135 In Vitro Generation of Cytolytic T Cells Against Human Melanoma Cells Overexpressing HDM2. A. SORURI, A. FAYYAZI, S. GANGL, C. GRIESINGER, C.A. ALBRECHT, T. SCHLOTT (Goettingen; Langen, Germany) .................................................................................................................................................... 2141 Artemisinin: An Alternative Treatment for Oral Squamous Cell Carcinoma. E. YAMACHIKA, T. HABTE, D. ODA (Seattle, WA, USA; Okayama City, Japan).............................................................................................. 2153 S19-mRNA Expression in Squamous Cell Carcinomas of the Upper Aerodigestive Tract. V. SENGPIEL, T. ROST, T. GÖRÖGH, I.O. RATHCKE, J.A.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache
    University of South Florida Masthead Logo Scholar Commons School of Information Faculty Publications School of Information 7-2015 A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache Authors: Jeffrey L. Jackson, Elizabeth Cogbill, Rafael Santana-Davila, Christina Eldredge, William Collier, Andrew Gradall, Neha Sehgal, and Jessica Kuester OBJECTIVE: To compare the effectiveness and side effects of migraine prophylactic medications. DESIGN: We performed a network meta-analysis. Data were extracted independently in duplicate and quality was assessed using both the JADAD and Cochrane Risk of Bias instruments. Data were pooled and network meta-analysis performed using random effects models. DATA SOURCES: PUBMED, EMBASE, Cochrane Trial Registry, bibliography of retrieved articles through 18 May 2014. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We included randomized controlled trials of adults with migraine headaches of at least 4 weeks in duration. RESULTS: Placebo controlled trials included alpha blockers (n = 9), angiotensin converting enzyme inhibitors (n = 3), angiotensin receptor blockers (n = 3), anticonvulsants (n = 32), beta-blockers (n = 39), calcium channel blockers (n = 12), flunarizine (n = 7), serotonin reuptake inhibitors (n = 6), serotonin norepinephrine reuptake inhibitors (n = 1) serotonin agonists (n = 9) and tricyclic antidepressants (n = 11). In addition there were 53 trials comparing different drugs. Drugs with at least 3 trials that were more effective than placebo for episodic migraines
    [Show full text]